Intravitreal Bevacizumab for Diabetic Macular Edema

This study is enrolling participants by invitation only.

Sponsored by:	Isfahan Ophthalmology Research Center
Information provided by:	Isfahan Ophthalmology Research Center
ClinicalTrials.gov Identifier:	NCT00703235

Purpose

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.

This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

Condition	Intervention	Phase
Macular Edema Diabetic Retinopathy	Drug: Bevacizumab	Phase II Phase III

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Diabetic Eye Problems Edema Retinal Disorders

Drug Information available for: Bevacizumab

U.S. FDA Resources

Study Type:

Interventional

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diabetes mellitus
Clinically significant macular edema
Possibility of performing macular OCT
Consent of patient for inclusion in the study

Exclusion Criteria:

History of macular photocoagulation in less than 6 months of inclusion in the study
Necessity of surgical intervention
Rejection of the remaining in the study by patient

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	MUI - clinical - 185290
Study First Received:	June 20, 2008
Last Updated:	June 20, 2008
ClinicalTrials.gov Identifier:	NCT00703235
Health Authority:	Iran: Ministry of Health

Study placed in the following topic categories:

Eye Diseases
Vascular Diseases
Diabetes Mellitus
Edema
Endocrine System Diseases
Macular Degeneration
Retinal Degeneration
Bevacizumab

Diabetic Angiopathies
Macular Edema
Signs and Symptoms
Diabetic Retinopathy
Endocrinopathy
Retinal Diseases
Diabetes Complications
Retinal degeneration

Additional relevant MeSH terms:

Antineoplastic Agents
Therapeutic Uses
Growth Substances
Physiological Effects of Drugs
Cardiovascular Diseases

Growth Inhibitors
Angiogenesis Modulating Agents
Angiogenesis Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009